3.13
Precedente Chiudi:
$3.27
Aprire:
$3.26
Volume 24 ore:
341.54K
Relative Volume:
0.58
Capitalizzazione di mercato:
$47.02M
Reddito:
-
Utile/perdita netta:
$-64.47M
Rapporto P/E:
-0.506
EPS:
-6.1852
Flusso di cassa netto:
$-52.33M
1 W Prestazione:
-7.12%
1M Prestazione:
-43.81%
6M Prestazione:
-45.09%
1 anno Prestazione:
-84.92%
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Nome
Jasper Therapeutics Inc
Settore
Industria
Telefono
(650) 549-1400
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Confronta JSPR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
JSPR
Jasper Therapeutics Inc
|
3.13 | 49.12M | 0 | -64.47M | -52.33M | -6.1852 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-08 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2025-07-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2025-07-07 | Downgrade | William Blair | Outperform → Mkt Perform |
2025-02-13 | Iniziato | UBS | Buy |
2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
2024-09-09 | Iniziato | JMP Securities | Mkt Outperform |
2024-07-08 | Iniziato | BTIG Research | Buy |
2024-06-27 | Iniziato | Stifel | Buy |
2024-05-06 | Iniziato | H.C. Wainwright | Buy |
2024-04-03 | Iniziato | Evercore ISI | Outperform |
2024-03-28 | Iniziato | RBC Capital Mkts | Outperform |
2024-03-18 | Iniziato | TD Cowen | Outperform |
2023-08-11 | Iniziato | CapitalOne | Overweight |
2022-02-28 | Iniziato | Cantor Fitzgerald | Overweight |
2021-11-08 | Iniziato | Credit Suisse | Outperform |
2021-10-21 | Iniziato | William Blair | Outperform |
2021-10-20 | Iniziato | BMO Capital Markets | Outperform |
2021-10-13 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
When is the best time to buy Jasper Therapeutics Inc. Equity Warrant stockConsistently high yield - jammulinksnews.com
What drives Jasper Therapeutics Inc. stock priceFree Daily Trading Room Entry - Autocar Professional
Jasper Therapeutics Inc. Equity Warrant Stock Analysis and ForecastBreakthrough stock performance - Autocar Professional
Is Jasper Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - jammulinksnews.com
What analysts say about Jasper Therapeutics Inc. Equity Warrant stockUnmatched market gains - Autocar Professional
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $29.75 Average Target Price from Analysts - Defense World
Jasper Therapeutics Inc. Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
What drives Jasper Therapeutics Inc. Equity Warrant stock priceFree Market Volatility Navigation Tips - jammulinksnews.com
Is Jasper Therapeutics Inc. Equity Warrant a good long term investmentFree Stock Market Return Analysis - jammulinksnews.com
What analysts say about Jasper Therapeutics Inc. stockMarket-beating performance - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc.JSPR - WV News
Trading (JSPR) With Integrated Risk Controls - news.stocktradersdaily.com
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
Jasper Therapeutics’ SWOT analysis: briquilimab stock faces pivotal moment - Investing.com
Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com
Bay Area biotech company's drug mishap leads to dozens of layoffs - SFGATE
HC Wainwright Issues Positive Estimate for JSPR Earnings - Defense World
Jasper Therapeutics' Data Crisis and the Investor's Dilemma: Fraud or Unfortunate Setback? - AInvest
Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP - MSN
Redwood City's Jasper Therapeutics Valuation Tumbles Amid Clinical Trial Setbacks and Layoffs - Hoodline
Jasper Therapeutics shares fall 1.99% after-hours as Schall Law Firm investigates securities law violations. - AInvest
JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):